Published in J Thromb Haemost on April 01, 2011
Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. Blood (2015) 1.44
Effects of an aqueous extract of dangguijagyagsan on serum lipid levels and blood flow improvement in ovariectomized rats. Evid Based Complement Alternat Med (2014) 1.42
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood (2017) 1.39
Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood (2013) 1.30
A ride with ferric chloride. J Thromb Haemost (2011) 1.09
Ferric chloride-induced murine carotid arterial injury: A model of redox pathology. Redox Biol (2013) 0.98
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation (2012) 0.94
Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion. J Clin Invest (2014) 0.93
RhoG protein regulates platelet granule secretion and thrombus formation in mice. J Biol Chem (2013) 0.90
Microvascular anastomosis guidance and evaluation using real-time three-dimensional Fourier-domain Doppler optical coherence tomography. J Biomed Opt (2013) 0.89
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood (2014) 0.88
Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol (2013) 0.87
Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction with free fatty acid receptor 4 in mice. J Am Heart Assoc (2015) 0.84
Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity. J Thromb Haemost (2016) 0.83
The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost (2012) 0.82
Endothelial PPAR-γ protects against vascular thrombosis by downregulating P-selectin expression. Arterioscler Thromb Vasc Biol (2015) 0.82
Plasmodium falciparum infection induces expression of a mosquito salivary protein (Agaphelin) that targets neutrophil function and inhibits thrombosis without impairing hemostasis. PLoS Pathog (2014) 0.81
Fibrin activates GPVI in human and mouse platelets. Blood (2015) 0.79
The effect of ferric chloride on superficial bleeding. Trauma Mon (2015) 0.79
Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood (2015) 0.78
Murine models in the evaluation of heparan sulfate-based anticoagulants. Methods Mol Biol (2015) 0.76
Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin. J Thromb Haemost (2016) 0.76
Thrombolytic effects of the snake venom disintegrin saxatilin determined by novel assessment methods: a FeCl3-induced thrombosis model in mice. PLoS One (2013) 0.76
Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice. Arterioscler Thromb Vasc Biol (2016) 0.76
Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity. PLoS One (2016) 0.75
Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1. Sci Rep (2016) 0.75
Antithrombotic potential of the contact activation pathway. Curr Opin Hematol (2016) 0.75
Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation. Intensive Care Med Exp (2015) 0.75
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest (1999) 2.34
Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med (2001) 1.75
Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost (2003) 1.72
Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J (1999) 1.72
The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett (1997) 1.70
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
Expression of an X-linked muscular dystrophy in a female due to translocation involving Xp21 and non-random inactivation of the normal X chromosome. Hum Genet (1984) 1.64
Restriction and modification in Bacillus subtilis: identification of a gene in the temperate phage SP beta coding for a BsuR specific modification methyltransferase. Mol Gen Genet (1980) 1.62
Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma. Gastroenterology (1992) 1.61
Disappearance rate of spermatozoa from the ejaculate following vasectomy. Fertil Steril (1969) 1.61
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol (2001) 1.59
Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice. J Thromb Haemost (2010) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A revised model of platelet aggregation. J Clin Invest (2000) 1.54
Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther (2004) 1.53
Urinary morbidity after 125I brachytherapy of the prostate. BJU Int (2003) 1.50
The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood (1998) 1.48
Selective advantage of fra (X) heterozygotes. Hum Genet (1990) 1.47
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
Countries' donation performance in perspective: time for more accurate comparative methodologies. Am J Transplant (2007) 1.45
The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. RNA (2001) 1.42
A point mutation in a type I procollagen gene converts glycine 748 of the alpha 1 chain to cysteine and destabilizes the triple helix in a lethal variant of osteogenesis imperfecta. J Biol Chem (1987) 1.41
The platelet glycoprotein GPIbbeta intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site. J Thromb Haemost (2009) 1.41
Young investigators. FASEB J (1990) 1.40
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1998) 1.40
Further evidence that fibrillar collagen is unable to promote platelet shape change and aggregation in the absence of secondary agonists. J Thromb Haemost (2005) 1.40
Headache after hematopoietic stem cell transplantation: being aware of chronic bilateral subdural hematoma. Leuk Lymphoma (2006) 1.40
The inhibition of the motility of human spermatozoa by various pharmacologic agents. Biol Reprod (1975) 1.35
ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol (1998) 1.35
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant (2011) 1.32
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol (1999) 1.29
Effects of (H + ), (Na + ), (K + ) and certain membrane-active drugs on glycolysis, motility, and ATP synthesis by human spermatozoa. Biol Reprod (1973) 1.28
Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol (2000) 1.26
The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell Mol Life Sci (2005) 1.26
CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J Virol (1997) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost (2005) 1.25
Neonatal stroke involving the middle cerebral artery in term infants: clinical presentation, EEG and imaging studies, and outcome. Dev Med Child Neurol (1995) 1.24
An endoscopic evaluation of the effects of non-steroidal anti-inflammatory drugs on the gastric mucosa. Gastrointest Endosc (1975) 1.23
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol (2005) 1.22
Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost (2000) 1.21
Bacterial contamination in platelet concentrates. Vox Sang (2014) 1.18
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation (2001) 1.17
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol (2010) 1.17
Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy (2008) 1.17
Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. Am J Hum Genet (2000) 1.16
The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol (1998) 1.15
The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett (2001) 1.15
Restriction and modification in Bacillus subtilis: two DNA methyltransferases with BsuRI specificity. I. Purification and physical properties. J Biol Chem (1981) 1.15
Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost (1997) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood (1999) 1.14
GM-2 gangliosidosis (Sandhoff's disease): two year follow-up by MRI. Neuroradiology (1994) 1.14
The human platelet ADP receptor activates Gi2 proteins. Biochem J (1995) 1.12
ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 1.12
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 1.11
Restriction and modification in Bacillus subtilis: two DNA methyltransferases with BsuRI specificity. II. Catalytic properties, substrate specificity, and mode of action. J Biol Chem (1981) 1.11
The effects of blood transfusions on PCR DNA typing at the CSF1P0, TP0X, TH01, D1S80, HLA-DQA1, LDLR, GYPA, HBGG, D7S8 and GC loci. J Forensic Sci (1997) 1.11
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy (2008) 1.11
BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood (2001) 1.10
Activation of ADP receptors and platelet function. Thromb Haemost (1997) 1.09
Glycoprotein (GP) Ib-IX-transfected cells roll on a von Willebrand factor matrix under flow. Importance of the GPib/actin-binding protein (ABP-280) interaction in maintaining adhesion under high shear. J Biol Chem (1999) 1.09
Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem (1993) 1.08
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol (1996) 1.07
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet (2001) 1.06
CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res (1992) 1.06
The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem (1999) 1.06
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia (2004) 1.06
[Progressive multifocal leukoencephalopathy (PML) in chronic lymphatic leukemia (CLL). Review of the literature and case report]. Nervenarzt (2002) 1.06
Measurement of low rates of oxygen consumption with a horizontal capillary-differential syringe manometer. Proc Soc Exp Biol Med (1967) 1.05
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant (2009) 1.05
Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet (1987) 1.04
CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg (2004) 1.04
Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. Biochemistry (2000) 1.03